Your browser is no longer supported. Please, upgrade your browser.
AMGN Amgen Inc. daily Stock Chart
Amgen Inc.
IndexS&P 500 P/E15.26 EPS (ttm)11.00 Insider Own0.20% Shs Outstand734.00M Perf Week-0.77%
Market Cap123.17B Forward P/E13.10 EPS next Y12.81 Insider Trans-0.45% Shs Float728.63M Perf Month-6.35%
Income8.17B PEG3.55 EPS next Q3.11 Inst Own81.10% Short Float1.07% Perf Quarter6.24%
Sales23.05B P/S5.34 EPS this Y13.10% Inst Trans-0.33% Short Ratio2.45 Perf Half Y-2.50%
Book/sh43.22 P/B3.88 EPS next Y1.93% ROA10.40% Target Price187.21 Perf Year-3.73%
Cash/sh53.44 P/C3.14 EPS next 5Y4.29% ROE26.60% 52W Range133.64 - 184.21 Perf YTD14.77%
Dividend4.60 P/FCF16.91 EPS past 5Y20.50% ROI13.00% 52W High-8.90% Beta1.36
Dividend %2.74% Quick Ratio5.80 Sales past 5Y8.10% Gross Margin82.20% 52W Low25.57% ATR2.52
Employees19200 Current Ratio6.20 Sales Q/Q2.10% Oper. Margin44.70% RSI (14)38.85 Volatility1.34% 1.36%
OptionableYes Debt/Eq1.11 EPS Q/Q17.80% Profit Margin35.50% Rel Volume0.81 Prev Close171.39
ShortableYes LT Debt/Eq1.06 EarningsJul 25 AMC Payout38.80% Avg Volume3.18M Price167.81
Recom2.40 SMA20-3.80% SMA50-2.50% SMA2003.69% Volume2,578,014 Change-2.09%
Jul-11-17Resumed Jefferies Buy
Jun-23-17Initiated Deutsche Bank Hold $172
Apr-05-17Downgrade Jefferies Buy → Hold
Mar-09-17Initiated UBS Neutral $185
Feb-01-17Upgrade BofA/Merrill Neutral → Buy
Dec-20-16Downgrade Credit Suisse Outperform → Neutral
Dec-13-16Initiated Oppenheimer Outperform
Nov-08-16Initiated Mizuho Buy $164
Aug-26-16Initiated Gabelli & Co Hold
Jun-29-16Initiated Bernstein Mkt Perform
Feb-25-16Initiated Citigroup Neutral $165
Feb-08-16Reiterated Argus Buy $202 → $185
Jan-20-16Initiated Credit Suisse Outperform $205
Dec-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-04-15Initiated Wells Fargo Market Perform
Oct-29-15Reiterated UBS Buy $168 → $180
Sep-01-15Initiated Raymond James Mkt Perform
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Jul-31-15Reiterated Deutsche Bank Buy $192 → $195
Jul-31-15Reiterated Barclays Equal Weight $180 → $185
Aug-17-17 04:00PM  Amgen And Humana Partner For Improved Health Outcomes And Efficiency PR Newswire
09:06AM  Where Amgens Enbrel and Nplate Stand after 2Q17 Market Realist
07:36AM  How Amgens Nephrology Drugs Are Positioned after 2Q17? Market Realist
Aug-16-17 05:10PM  Repatha® (Evolocumab) Phase 3 Cognitive Function Study Results Published In The New England Journal Of Medicine PR Newswire
10:36AM  What We May See from Amgens Vectibix in 2017 Market Realist
10:08AM  Biogen: Goldman Has Conviction!
09:07AM  How Amgens Neutropenia Drugs Are Positioned after 2Q17 Market Realist
08:01AM  See what the IHS Markit Score report has to say about Amgen Inc. Markit
07:36AM  What Amgen Expects from Blincyto in 2017 Market Realist
Aug-15-17 10:36AM  How Amgens Repatha Performed in 2Q17 Market Realist
10:09AM  Can Ligand's Captisol Deals Boost Growth in the Long Run? Zacks
09:07AM  Gauging Amgens Xgeva Contribution in 2017 Market Realist
09:05AM  Are Amgen's New Drugs Doing Well Enough to Drive Sales? Zacks
07:38AM  What Kyprolis Could Do for Amgens Revenue Growth Market Realist
Aug-14-17 04:36PM  Behind Amgens High Revenue Growth from Prolia in 2Q17 Market Realist
02:36PM  Inside Amgens 2Q17 Performance Market Realist
01:06PM  What Amgens Analysts Recommend in August 2017 Market Realist
11:43AM  The Zacks Analyst Blog Highlights: Disney, Amgen, Caterpillar, S&P Global and Emerson Electric Zacks
10:37AM  Pfizers Major Growth Drivers in 2Q17 Market Realist
07:40AM  Dividend Coverage: This Biotech Drugmaker Pays Higher Dividend than the Healthcare Sector by Over 316%; Will Trade Ex-Dividend on August 15, 2017 ACCESSWIRE
Aug-12-17 09:50PM  Edited Transcript of AMGN earnings conference call or presentation 25-Jul-17 9:00pm GMT Thomson Reuters StreetEvents
08:00AM  See what the IHS Markit Score report has to say about Amgen Inc. Markit
Aug-11-17 05:04PM  Top Analyst Reports for Disney, Amgen & Caterpillar Zacks
04:52PM  ETFs with exposure to Amgen, Inc. : August 11, 2017 Capital Cube
10:19AM  Amgen, Inc. breached its 50 day moving average in a Bearish Manner : AMGN-US : August 11, 2017 Capital Cube
08:00AM  IHS Markit Score Update: Drop in demand for ETFs holding Amgen Inc is a negative sign for its shares Markit
Aug-10-17 09:07AM  Celgenes Otezla Witnessed High Revenue Growth in 2Q17 Market Realist
08:50AM  Major Biotechs Send Short Sellers Running for Cover 24/7 Wall St.
08:00AM  See what the IHS Markit Score report has to say about Amgen Inc. Markit
07:38AM  Trade of the Day: Amgen, Inc. (AMGN) Stock Is a Quiet Bull InvestorPlace
Aug-09-17 01:02PM  Analysts Recommendations for Celgene in August 2017 Market Realist
08:00AM  See what the IHS Markit Score report has to say about Amgen Inc. Markit
Aug-08-17 11:31AM  Valeant Pops on Earnings Beat, Debt Reduction Effort
11:14AM  Ligand (LGND) Q2 Earnings & Revenues Top, 2017 View Raised Zacks
09:31AM  Amgen Remains A Standout Among Biotechs Forbes
02:00AM  Scottish Medicines Consortium Accepts Amgen's Multiple Myeloma Treatment, KYPROLIS® (carfilzomib), in Combination with Dexamethasone, for use at First Relapse PR Newswire
Aug-07-17 04:19PM  Here's Why Array BioPharma Inc. Fell 13.7% in July Motley Fool
09:08AM  Why A Tax Holiday Alone Won't Spark Biotech M&A
Aug-05-17 11:52AM  Earnings Preview: What To Expect From Valeant Pharmaceuticals On Tuesday Forbes
Aug-03-17 04:23PM  The Surprising Reason Regeneron Toppled Despite Its Beat-And-Raise Investor's Business Daily
Aug-02-17 11:01AM  Earnings Preview: What To Expect From Teva Pharmaceutical On Thursday Forbes
08:32AM  Biotech Stock Roundup: Q2 Earnings from Gilead, CELG & More, Dynavax Up on Panel Vote Zacks
Aug-01-17 12:26AM  3 ETFs to Watch Out for on Biotech Earnings Zacks
Jul-31-17 04:46PM  Express Scripts to cover Mylan's EpiPen, exclude rivals Reuters
09:10AM  Amgen Submits Supplemental Biologics License Application For Prolia® (denosumab) In Glucocorticoid-Induced Osteoporosis PR Newswire
09:00AM  Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 980 To US Food And Drug Administration PR Newswire
Jul-30-17 03:20PM  Court Ruling on 'Biosimilars' Sets Stage for More Drug Acquisitions
Jul-28-17 04:01PM  Amgen Announces 2017 Third Quarter Dividend PR Newswire
12:37PM  Amgen, Inc. :AMGN-US: Earnings Analysis: Q2, 2017 By the Numbers : July 28, 2017 Capital Cube
Jul-27-17 06:19PM  Amgen gets fast U.S. FDA review for adding heart benefits to cholesterol drug label Reuters
05:49PM  FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha® (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events PR Newswire
10:44AM  Company News for July 27, 2017 Zacks
08:00AM  Today's Research Reports on Stocks to Watch: Amgen and United States Steel Corporation ACCESSWIRE
01:07AM  Asian shares gain on strong earnings, dovish Fed policy Associated Press
Jul-26-17 04:33PM  'Poor Quality' Amgen Earnings Beat Doesn't Impress These Two Wall Street Analysts Benzinga
02:47PM  Amgen: It's Never Just About the Earnings
01:52PM  Amgen turned in a strong second quarter but analysts say things are looking bleak MarketWatch
12:51PM  US STOCKS-Strong earnings power Wall St to record; Fed awaited Reuters
11:31AM  US STOCKS-Boeing, AT&T power Wall St to record; Fed in focus Reuters
11:02AM  Amgen shares drop as earnings report reveals embarrassingly bare drug pipeline CNBC
10:09AM  Amgen, Inc. (AMGN) Stock Is a Trade for Ailing Portfolios InvestorPlace
09:58AM  Amgen (AMGN) Stock Falls Despite Q2 Earnings & Sales Beat Zacks
09:35AM  Short Sellers Run for Cover From Major Biotech Stocks 24/7 Wall St.
08:30AM  2 Incredibly Cheap Dividend Stocks Motley Fool
08:15AM  Biotech Stock Roundup: Amgen, Biogen Top Q2 Estimates, Update on Incyte RA Drug Zacks
08:07AM  Early movers: KO, BA, F, DHI, HLT, ANTM, NOC, T, APRN, AMGN & more CNBC
Jul-25-17 09:52PM  Evening Movers: Chipotle Gains, Amgen Falls, US Steel Soars
09:24PM  Amgen beats Street 2Q forecasts Associated Press
05:30PM  Biotech still has more room to run: Technician CNBC Videos
05:02PM  Amgen Topples After Increased Forecast Still Lags Some Views Investor's Business Daily
04:27PM  Amgen shares down 3% after company's guidance on lower end of expectations MarketWatch
04:07PM  Amgen 2nd quarter profit tops Street estimates, raises forecast Reuters
04:07PM  Amgen beats on top line CNBC Videos
04:01PM  Amgen Reports Second Quarter 2017 Financial Results PR Newswire
Jul-24-17 05:24PM  Shrinking dollar could boost the market and make these stocks big winners CNBC
11:51AM  2 Ways To Trade This Week's Healthcare Earnings Benzinga
10:11AM  Surprise in Store for Healthcare in Q2: Buy Top-Ranked ETFs Zacks
08:16AM  Big Pharma Q2 Earnings Releases on Jul 25: LLY, BIIB, AMGN Zacks
Jul-23-17 04:19PM  Five Unappreciated Stocks With High Return On Invested Capital Forbes
11:50AM  3 Stocks That Are Absurdly Cheap Right Now Motley Fool
Jul-21-17 07:40PM  [$$] Clinical Development News, July 17-21 The Wall Street Journal
04:09PM  FDA Accepts Amgen's Biologics License Application for Aimovig
01:38PM  Will Gilead Beat 2Q Earnings? PerhapsBut Does It Matter?
08:48AM  Amgen (AMGN) to Report Q2 Earnings: What's in the Cards? Zacks
07:15AM  3 Dividend Stocks That Thrive in Market Crashes Motley Fool
Jul-20-17 04:30PM  FDA Accepts Biologics License Application For Aimovig (erenumab) PR Newswire
04:00PM  Amgen Announces Webcast of 2017 Second Quarter Financial Results PR Newswire
Jul-19-17 02:30PM  Biotech Stocks On Verge Of Next Major Move Up Investopedia
08:39AM  Biotech Stock Roundup: Vertex Boosted by CF Data, FDA Nod for Gilead, Puma Drugs Zacks
08:04AM  3 Dividend Stocks That Thrive in Both Bull and Bear Markets Motley Fool
07:33AM  Poor test results for Roche cloud growth prospects Reuters
Jul-18-17 02:27PM  Which Biotech Earnings Will Outperform?
12:03PM  Colorado biotech makes deal with industry giant American City Business Journals
10:37AM  Ligand Signs Agreement with Amgen, Grants Rights to Captisol Zacks
08:00AM  Amgen And Array BioPharma Announce Preclinical License And Collaboration Agreement In Inflammation PR Newswire
07:20AM  Featured Company News Amgen Submits Regulatory Applications in US, Europe to Include Overall Survival Data in KYPROLIS Label Accesswire
Jul-17-17 10:46AM  Amgen FDA Letter Isn't A Surprise (Or A Concern), Says Jefferies
10:29AM  Amgen (AMGN) Gets CRL for Osteoporosis Drug Evenity's BLA Zacks
Jul-16-17 06:00PM  Amgen And UCB Provide Update On Regulatory Status Of EVENITY (romosozumab) In The US PR Newswire
Jul-14-17 03:46PM  Amgen Applies to Have Kyprolis' Label Updated
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary artery diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Erenumab for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; AMJEVITA to treat psoriatic arthritis and polyarticular juvenile idiopathic arthritis, as well as ankylosing spondylitis and rheumatoid arthritis; ABP 215 for biosimilar candidates; and ABP 980 to treat human epidermal growth factor receptor 2-positive early breast cancer. The company's other marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc.; Array BioPharma Inc.; and Syngene International Limited. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BALTIMORE DAVIDDirectorMay 31Sale153.933,700569,54131,159Jun 02 07:21 PM
Patton Cynthia MSVP & CCOMay 24Sale154.402,922451,16421,292May 24 07:35 PM
de Carbonnel FrancoisDirectorSep 09Option Exercise71.645,000358,20021,171Sep 13 06:21 PM